NORGANOID offers an automated organ‑on‑chip platform (NLS™) that generates and cultures human organoids from iPSC sources in a microfluidic environment for high‑content drug screening. The system combines plug‑and‑play hardware with computer‑vision and AI to monitor organoid health, capture phenotypic data, and predict safety and efficacy, providing pharmaceutical, biotech, and academic researchers a scalable, cost‑effective alternative to 2D cultures and animal models.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional preclinical drug testing relies on 2D cell cultures and animal models that fail to capture the three‑dimensional architecture, cellular diversity, and microenvironment of human tissues, leading to low predictive power for clinical outcomes.
Solution
NORGANOID provides an automated, scalable organ‑on‑chip (OoC) platform called NLS™ that generates human organoids from induced pluripotent stem cells and maintains them in a microfluidic environment for high‑content screening. The system integrates plug‑and‑play hardware with computer‑vision and AI algorithms to monitor organoid health, capture phenotypic data, and assess drug safety and efficacy with greater physiological relevance. By standardizing organoid production, culture, and imaging, NORGANOID reduces manual labor, material costs, and variability, enabling faster, more reliable preclinical experiments that are closer to clinical reality. Researchers can access the platform as a turnkey solution or as a service, allowing rapid adoption without extensive in‑house expertise.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic research labs, that need physiologically relevant, high‑throughput models for drug discovery, toxicology, and precision‑medicine studies.
Features
- Fully automated microfluidic organ‑on‑chip hardware that supports iPSC differentiation, organoid maturation, and long‑term culture
- Integrated computer‑vision pipeline for real‑time monitoring of organoid morphology, viability, and functional readouts
- AI‑driven data analysis that quantifies phenotypic responses and predicts drug safety and efficacy
- Plug‑and‑play workflow compatible with standard imaging systems and high‑throughput plate formats
- Cost‑effective design that minimizes reagent consumption and capital expenditure compared with conventional robotic cell‑culture platforms
- Scalable architecture suitable for large‑scale screening campaigns across multiple organoid types